Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Medifast (MED) Depreciation and Depletion (2024 - 2025)

Medifast's Depreciation and Depletion history spans 2 years, with the latest figure at $2.6 million for Q4 2025.

For Q4 2025, Depreciation and Depletion rose 13.04% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $10.5 million, down 39.66%, while the annual FY2025 figure was $10.5 million, 39.66% down from the prior year.
Depreciation and Depletion reached $2.6 million in Q4 2025 per MED's latest filing, up from $2.5 million in the prior quarter.
In the past five years, Depreciation and Depletion ranged from a high of $10.5 million in Q2 2024 to a low of $2.3 million in Q1 2024.